美股A股
StockGist
Back to ECG
Q1 20262026-05-06· deepseek:deepseek-v4-flash

ECG earnings call summary

Prepared Highlights

Prepared Metrics

MetricValueSpeaker/Context
Q1 revenue$1.04B, +25% YoY(CFO)(prepared)
Q1 EBITDA$88.9M, +44% YoY(CFO)(prepared)
Q1 EBITDA margin8.6%, +110 bps YoY(CFO)(prepared)
E&M Q1 revenue$835.1M, +29% YoY(CFO)(prepared)
E&M Q1 EBITDA / margin$75.3M / 9.0%, +140 bps YoY(CFO)(prepared)
T&D Q1 revenue$204.4M, +10.5% YoY(CFO)(prepared)
T&D Q1 EBITDA / margin$27.1M / 13.3%, +240 bps YoY(CFO)(prepared)
Backlog$3.68B, +20% YoY(CFO)(prepared)
Q1 operating cash flow$143.7M vs $7.1M prior year(CFO)(prepared)
Q1 FCF$131.9M vs -$8.1M prior year(CFO)(prepared)
Q1 CapEx$15.5M vs $18.5M prior year(CFO)(prepared)
Cash / gross debt / credit availability$275M / $281.2M / $222.8M(CFO)(prepared)
Pro forma net leverage~0.5x as of Apr 2(CFO)(prepared)
2026 revenue guidance$4.3B–$4.4B(CFO)(prepared)
2026 EBITDA guidance$345M–$360M(CFO)(prepared)
2026 EBITDA margin at guidance midpoint8.1%(CFO)(prepared)
Legacy business balance-of-year EBITDA margin~8%(CFO)(prepared)
SCNM 2025 revenue / EBITDA margin$109M / high-teens(CFO)(prepared)

Q&A Batch (1-4 of 4)

Q1 — Brian Daniel Brophy

Q2 — Mike(代 Joe)

Q3 — Shweta(代 Manish)

Q4 — Christopher Senyek